Patricia Sheean1, Huifang Liang2, Linda Schiffer3, Claudia Arroyo3, Melinda Stolley4. 1. Marcella Niehoff School of Nursing, Loyola University Chicago, Health Sciences Campus, 2160 South First Avenue, Building 120, Room 4527, Maywood, IL, 60153, USA. psheean1@luc.edu. 2. Takeda Development Center Americas, Inc., One Takeda Parkway, Deerfield, IL, 60015, USA. 3. Division of Academic Internal Medicine and Geriatrics, University of Illinois at Chicago, 1747 West Roosevelt Road, Room 558, MC 275, Chicago, IL, 60608, USA. 4. Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Abstract
PURPOSE: Metabolic Syndrome (MetS) is more predominant in overweight, obese and minority populations. This study examined the prevalence of MetS in an exclusively African-American (AA) cohort of breast cancer (BC) survivors; an underrepresented group in previous studies demonstrating negative BC outcomes disparities for females with MetS. METHODS: Using a case-control design, overweight/obese AA women with treated Stage I-IIIa BC were matched 1:1 on age, race, sex, and body mass index (BMI) category with non-cancer population controls (n = 444). Three of the following conditions were used to define MetS: HDL cholesterol <50 mg/dL (1.3 mmol/L), serum triglycerides ≥150 mg/dL (1.7 mmol/L), blood glucose ≥100 mg/dL (or on treatment), waist circumference ≥88 cm, or ≥130 mmHg systolic or ≥85 mmHg diastolic blood pressure (or on treatment). Matched-pairs analyses were conducted. RESULTS: For BC cases, most women had self-reported Stage I (n = 76) or Stage II (n = 91) disease and were 6.9 (±5.2) years post-diagnosis. MetS was significantly lower in BC survivors vs. their non-cancer population controls (43.2 vs. 51.4 %, respectively; p < 0.05). The diagnosis of MetS did not differ by BMI stratification. A lower prevalence of ≥2 risk factors (80.2 vs. 85.6 %, p < 0.05) was observed for all cases vs. CONCLUSIONS: While MetS occurred less frequently in our BC cases vs. non-cancer controls, our estimates are nearly two times those reported in other BC survivors, suggesting important racial/ethnic differences. IMPLICATIONS FOR CANCER SURVIVORS: The prognostic implications of MetS among AA BC survivors remain unknown and warrant further investigation.
PURPOSE:Metabolic Syndrome (MetS) is more predominant in overweight, obese and minority populations. This study examined the prevalence of MetS in an exclusively African-American (AA) cohort of breast cancer (BC) survivors; an underrepresented group in previous studies demonstrating negative BC outcomes disparities for females with MetS. METHODS: Using a case-control design, overweight/obese AA women with treated Stage I-IIIa BC were matched 1:1 on age, race, sex, and body mass index (BMI) category with non-cancer population controls (n = 444). Three of the following conditions were used to define MetS: HDL cholesterol <50 mg/dL (1.3 mmol/L), serum triglycerides ≥150 mg/dL (1.7 mmol/L), blood glucose ≥100 mg/dL (or on treatment), waist circumference ≥88 cm, or ≥130 mmHg systolic or ≥85 mmHg diastolic blood pressure (or on treatment). Matched-pairs analyses were conducted. RESULTS: For BC cases, most women had self-reported Stage I (n = 76) or Stage II (n = 91) disease and were 6.9 (±5.2) years post-diagnosis. MetS was significantly lower in BC survivors vs. their non-cancer population controls (43.2 vs. 51.4 %, respectively; p < 0.05). The diagnosis of MetS did not differ by BMI stratification. A lower prevalence of ≥2 risk factors (80.2 vs. 85.6 %, p < 0.05) was observed for all cases vs. CONCLUSIONS: While MetS occurred less frequently in our BC cases vs. non-cancer controls, our estimates are nearly two times those reported in other BC survivors, suggesting important racial/ethnic differences. IMPLICATIONS FOR CANCER SURVIVORS: The prognostic implications of MetS among AA BC survivors remain unknown and warrant further investigation.
Entities:
Keywords:
African-American; Breast cancer; Case control; Metabolic syndrome; Survivorship
Authors: Marilyn L Kwan; Wendy Y Chen; Candyce H Kroenke; Erin K Weltzien; Jeannette M Beasley; Sarah J Nechuta; Elizabeth M Poole; Wei Lu; Michelle D Holmes; Charles P Quesenberry; John P Pierce; Xiao Ou Shu; Bette J Caan Journal: Breast Cancer Res Treat Date: 2011-12-21 Impact factor: 4.872
Authors: Jiankang Liu; Sean Coady; J Jeffery Carr; Udo Hoffmann; Herman A Taylor; Caroline S Fox Journal: Obesity (Silver Spring) Date: 2014-02-11 Impact factor: 5.002
Authors: Peter T Katzmarzyk; George A Bray; Frank L Greenway; William D Johnson; Robert L Newton; Eric Ravussin; Donna H Ryan; Steven R Smith; Claude Bouchard Journal: Am J Clin Nutr Date: 2009-10-14 Impact factor: 7.045
Authors: Patricia Sheean; Lauren Matthews; Alexis Visotcky; Anjishnu Banerjee; Andrea Moosreiner; Kimberly Kelley; Christopher R Chitambar; Paula E Papanek; Melinda Stolley Journal: Breast Cancer Res Treat Date: 2021-03-19 Impact factor: 4.624
Authors: Temidayo Fadelu; Ruth Damuse; Joarly Lormil; Elizabeth Pecan; Lauren Greenberg; Cyrille Dubuisson; Viergela Pierre; Scott A Triedman; Lawrence N Shulman; Timothy R Rebbeck Journal: JCO Glob Oncol Date: 2020-10